Wedbush Reaffirms “Outperform” Rating for Oruka Therapeutics (NASDAQ:ORKA)

Oruka Therapeutics (NASDAQ:ORKA)‘s stock had its “outperform” rating reaffirmed by Wedbush in a research note issued to investors on Thursday,Benzinga reports. They currently have a $40.00 target price on the stock. Wedbush’s price objective indicates a potential upside of 297.61% from the stock’s current price. Wedbush also issued estimates for Oruka Therapeutics’ FY2029 earnings at ($4.14) EPS.

A number of other brokerages also recently weighed in on ORKA. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, February 7th. Wolfe Research started coverage on shares of Oruka Therapeutics in a research note on Tuesday, February 4th. They issued an “outperform” rating and a $20.00 target price on the stock. Seven research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $39.86.

Oruka Therapeutics Stock Up 6.3%

Shares of NASDAQ:ORKA opened at $10.06 on Thursday. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13. The firm has a market capitalization of $376.66 million, a PE ratio of -1.61 and a beta of 0.25. The company has a 50-day moving average price of $9.86 and a two-hundred day moving average price of $14.87.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. Analysts anticipate that Oruka Therapeutics will post -3.41 earnings per share for the current fiscal year.

Institutional Trading of Oruka Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. purchased a new position in Oruka Therapeutics during the fourth quarter valued at $54,000. AlphaCentric Advisors LLC purchased a new position in Oruka Therapeutics during the fourth quarter valued at $119,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Oruka Therapeutics in the 4th quarter worth about $144,000. Squarepoint Ops LLC purchased a new position in shares of Oruka Therapeutics in the 4th quarter worth about $236,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in shares of Oruka Therapeutics in the 4th quarter worth about $303,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.